LONDON, UK, 20 May 2008, Curidium Medica plc, (LSE: CUR), a personalized medicine company focused on bringing the right drug to the right patient, announced today that director Rob Smith, Finance Director, today has purchased 1,825 ordinary shares in the Company at a price of 54.8 pence per share.
